Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
The S.Korean pharmaceutical company aims to expand its CMO business for syringes for domestic and foreign companies
By Feb 20, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Celltrion Pharm's Cheongju plant in South Korea](https://www.kedglobal.com/data/ked/image/2023/02/20/ked202302200016.700x.0.png)
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for its pre-filled syringe production facility.
The company said it passed an inspection by Brazil’s National Health Surveillance Agency (ANVISA) at the end of last year at its plant in Cheongju, South Korea. The certification will allow Celltrion to produce and supply syringes to South America.
Celltrion also said it plans to undergo inspections by authorities in Japan and the US this year.
The company's syringe facility received approval from both Korea's Ministry of Food and Drug Safety and the EU in 2021, and started commercial production of autoimmune disease treatments Remsima SC and Yuflyma last year.
A Celltrion official said the company aims to expand its contract manufacturing business for syringes for domestic and foreign companies targeting the global market, and continue to grow through portfolio expansion.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Bio & PharmaCelltrion applies for EMA approval of smaller dose formulation of Yuflyma
Jan 16, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
Jan 11, 2023 (Gmt+09:00)
1 Min read -
Comment 0
LOG IN